Earlier, in January India's Drug Technical Advisory Board (DTAB), India's apex drug advisory body, deliberated on the issue of same brand name (including look-alike and sound-alike ones) for different category of products and it suggested that to ensure patient safety, the manufacturing and marketing of different drugs with same brand name should "not be allowed."
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.